NEW YORK (GenomeWeb) – CollabRx and Medytox today announced they have reached a definitive merger agreement.
Under the terms of the deal, CollabRx shareholders will own a 10 percent stake in the combined company, of which it will operate as a wholly owned subsidiary. Medytox shareholders will own the remaining 90 percent. Further terms of the deal were not disclosed.
The companies previously entered into a non-binding letter of intent to negotiate a merger.